NASDAQ:ALNY Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis $269.53 -2.02 (-0.74%) (As of 10/3/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$268.35▼$272.4950-Day Range$233.81▼$287.0152-Week Range$141.98▼$287.55Volume678,404 shsAverage Volume875,650 shsMarket Capitalization$34.09 billionP/E RatioN/ADividend YieldN/APrice Target$279.14Consensus RatingModerate Buy Company OverviewAlnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.Read More… The death of Nvidia? (Ad)Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.So go here now to read my new report The Big AI Die-Up… while you still can. Alnylam Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks80th Percentile Overall ScoreALNY MarketRank™: Alnylam Pharmaceuticals scored higher than 80% of companies evaluated by MarketBeat, and ranked 225th out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingAlnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 17 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageAlnylam Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Alnylam Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($2.73) to ($2.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alnylam Pharmaceuticals is -100.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alnylam Pharmaceuticals is -100.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Alnylam Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.52% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAlnylam Pharmaceuticals has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alnylam Pharmaceuticals has recently increased by 18.04%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlnylam Pharmaceuticals does not currently pay a dividend.Dividend GrowthAlnylam Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.52 Percentage of Shares Shorted3.52% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAlnylam Pharmaceuticals has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alnylam Pharmaceuticals has recently increased by 18.04%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News Sentiment0.91 News SentimentAlnylam Pharmaceuticals has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Alnylam Pharmaceuticals this week, compared to 10 articles on an average week.Search Interest6 people have searched for ALNY on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -86% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Alnylam Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,446,733.00 in company stock.Percentage Held by InsidersOnly 1.50% of the stock of Alnylam Pharmaceuticals is held by insiders.Percentage Held by Institutions92.97% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alnylam Pharmaceuticals' insider trading history. ALNY Stock News HeadlinesAlnylam Stock Soars 65%: Find Out What’s Behind the GainsAlnylam Pharmaceutical is on the move. In early to mid-2025, the FDA is expected to approve expanded use of a key drug.September 12, 2024 | marketbeat.comBuy Rating Affirmed for Alnylam Pharma on Strong Phase 3 Trial Results and Favorable Sales ForecastOctober 1 at 3:59 PM | markets.businessinsider.comThe massive trade idea that’s being censoredThere is a red-hot sector right now that it seems like Google doesn’t want us to talk about… Because when we talk about it in email, sometimes those messages have trouble making it through to you. And it’s not just email! Videos from Youtube are also being removed. We don’t know exactly why it’s happening… Or if it’s being done manually or by an algorithm…. But we do know that you probably are going to want to see what they’re censoring.October 3, 2024 | DTI (Ad)Not Holding Alnylam Pharmaceuticals (ALNY) Hurt Fidelity Growth Strategies Fund’s PerformanceOctober 1 at 10:58 AM | msn.comAlnylam Pharma’s Promising Clinical Data Tempered by Market Factors in Hold Rating AssessmentSeptember 30 at 8:55 AM | markets.businessinsider.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $279.14 Consensus Target Price from BrokeragesSeptember 30 at 1:53 AM | americanbankingnews.comAlnylam : Phase 3 Study Data Support Potential Of Vutrisiran In ATTR Amyloidosis With CardiomyopathySeptember 29, 2024 | markets.businessinsider.comAlnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024September 29, 2024 | businesswire.comSee More Headlines ALNY Stock Analysis - Frequently Asked Questions How have ALNY shares performed this year? Alnylam Pharmaceuticals' stock was trading at $191.41 at the beginning of 2024. Since then, ALNY shares have increased by 40.8% and is now trading at $269.53. View the best growth stocks for 2024 here. How were Alnylam Pharmaceuticals' earnings last quarter? Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced its earnings results on Thursday, August, 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.74) by $0.61. The business's revenue was up 107.0% compared to the same quarter last year. Who are Alnylam Pharmaceuticals' major shareholders? Alnylam Pharmaceuticals' top institutional shareholders include SG Americas Securities LLC and Park Avenue Securities LLC. Insiders that own company stock include Yvonne Greenstreet, Jeffrey V Poulton, Akshay Vaishnaw, Michael W Bonney, Pushkal Garg, Kevin Joseph Fitzgerald, Amy W Schulman, Tolga Tanguler, Steven M Paul, Dennis A Ausiello, David E I Pyott, Indrani Lall Franchini and John Maraganore. View institutional ownership trends. How do I buy shares of Alnylam Pharmaceuticals? Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Alnylam Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI) and Mylan (MYL). Company Calendar Last Earnings8/01/2024Today10/03/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALNY CUSIP02043Q10 CIK1178670 Webwww.alnylam.com Phone(617) 551-8200Fax617-551-8101Employees2,100Year Founded2002Price Target and Rating Average Stock Price Target$279.14 High Stock Price Target$400.00 Low Stock Price Target$159.00 Potential Upside/Downside+2.8%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage24 Analysts Profitability EPS (Most Recent Fiscal Year)($2.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-440,240,000.00 Net Margins-3.11% Pretax Margin-2.63% Return on EquityN/A Return on Assets-1.88% Debt Debt-to-Equity RatioN/A Current Ratio3.01 Quick Ratio2.93 Sales & Book Value Annual Sales$2.34 billion Price / Sales14.65 Cash FlowN/A Price / Cash FlowN/A Book Value($1.76) per share Price / Book-154.29Miscellaneous Outstanding Shares126,492,000Free Float124,595,000Market Cap$34.35 billion OptionableOptionable Beta0.38 Social Links This page (NASDAQ:ALNY) was last updated on 10/3/2024 by MarketBeat.com Staff From Our PartnersThe world’s smartest man is in their crosshairsElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredNo matter the outcome of the election, it could be a death sentence for your wealth...In today's financial landscape, many investors are feeling disillusioned and disappointed with traditional inv...Allegiance Gold | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredMassive NVIDIA Sell-Off: Are We Headed for a Market Collapse?You may have heard about NVIDIA's CEO dumping shares of his own company. He sold 4.4 million shares this ye...Behind the Markets | SponsoredHow a $200,000 Mistake Unlocked a $118 Billion Gold TreasureThe window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.Monument Traders Alliance | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Alnylam Pharmaceuticals, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.